

July 4, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,


Sub: Press Release - Alivira registers three products in Ukraine

We are pleased to enclose hereby a press release of the Company titled "Alivira registers three products in Ukraine"

Kindly take the same on record.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited


Krupesh Mehta
Company Secretary

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7,Road No. 22, Wagle Industrial Area, Thane (W), Mumbai – 400604, India

Tel: +91 22 41114777 | **FAX:** +91-22-41114754 | **CIN:** L99999MH1985PLC036685

<http://www.sequent.in>



Alivira registers three products in Ukraine

Expands its offerings to ninth largest egg producing market

Mumbai, July 4 ,2017 - SeQuent Scientific Limited ("SeQuent") today announced that its subsidiary Alivira has received three product registrations in Ukraine. The products have already been shipped to Ukraine and will be launched shortly.

Ukraine is the largest egg and poultry market in Europe growing at over 8% year on year largely on account of expanding exports to European Union, Middle East, and Asia.

Alivira entered Ukraine in October 2016 and has since developed and initiated registration of a strong portfolio of nutrition products which bode well with the market's transition from traditional antibiotics towards nutrition. Ukraine would make a significant contribution to Alivira's growth as another six products are under registration.

Commenting on the development, **Mr. Manish Gupta, Managing Director of Alivira** said *"We are happy to have made an organic foray into Ukraine, which is a dominant poultry market in the World. Alivira's differentiated product profile is well poised to drive the industry's transition from treatment to prevention products. Our entry into Ukraine sets us up nicely to cement and expand our business interests in other CIS countries."*

About Alivira Animal Health Limited

Alivira Animal Health Limited ("Alivira"), a wholly-owned subsidiary of SeQuent is a vertically integrated Animal Healthcare company with six state-of-the-art manufacturing facilities including the USFDA approved API facility at Vizag(India). The Company's API business is characterised by new product development capability, best-in-class infrastructure, broad product range and long-term relationships with most of the global animal health companies. In the formulations space, Alivira has an established business presence in India, Turkey, Europe, Latam, Africa, MENA and South East Asia. It has close to 450 products across 12 dosage forms focused towards production animals produced in GMP compliant facilities in Spain, Turkey, Brazil and India. Alivira's long-term vision is to become a global powerhouse for animal health built on a platform of superior quality and compliance.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has nine manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

For Queries, please contact

Tushar Mistry

Chief Financial Officer

Tel: +91 22 41114717

Tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations

Tel : +91 22 42150210

dpingle@christensenir.com

Registered Office

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle', Plot No. E7, Road
No. 22, Wagle Industrial Area, Thane (W),
Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | **ISIN:** INE807F01019

REUTERS: SEQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.